v3.26.1
Revenue
3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company earns substantially all of its revenue from investment advisory, medical device operations (including software licensing, fee-per-test, and hardware sales), and other investment management services. The table below summarizes the Company's investment advisory fees, medical device revenues, and other revenue (in thousands):
SuccessorPredecessor
Three Months Ended
March 31, 2026
Three Months Ended
March 31, 2025
Investment advisory fees$1,347 $1,416 
Medical device revenues1,370 — 
Other revenue43 
Total revenue$2,760 $1,423 
No individual customer accounted for 10% or greater of revenue for any period.